mechanism of glp-1 receptor agonists Frontiers GLP-1 receptor agonists (GLP-1RAs): cardiovascular
Description
Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial
According to the Cleveland Clinic, the higher the dose of the GLP-1 agonist, the more extreme the effects
Declaration of interests R.E.K., B.B-G., C.L.B., T.G., K.G.M., K.R.H., W.F.J.H., D.H.I., S.L., T.K., S.B.P., A.S., A.V., and K.R
Class safety (regulatory labeling): the boxed warning and monitoring guidance are extrapolated from the broader FDA/EMA GLP-1 class labeling, not yet from a Retatrutide-specific approved label (there isnt one)
therefore, letrozole is considered first-line therapy
Important Rule Wegovy and Zepbound are not covered by Medicare for obesity
